# Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis

> **NCT07756268** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** SYS6020 injection

## Key facts

- **NCT ID:** NCT07756268
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-16
- **Primary completion:** 2029-02-07
- **Final completion:** 2029-02-07
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07756268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07756268, "Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07756268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*